Recent scientific studies have shown that taking Ozempic, particularly at higher doses, can cause gastroparesis
While the observed difference between groups in treatment discontinuation due to lack of effect was relatively smaller, it was still differential (0.7% in the semaglutide 2.4 mg group and 2.8% in the placebo group) and therefore does not completely negate the potential impact on reporting and performance biases (i.e., relatively less concerning for biases)
It is unknown whether WEGOVY causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined [see Warnings and Precautions (5.1), Nonclinical Toxicology (13.1)]
This combination of medication and behavior change gives patients the best chance of long-term success
The Danish Medicines Agency has reported 19 cases of NAION among Ozempic users in Denmark and noted a sharp rise in overall cases since the drugs market introduction in 2018